The Treg cell-based therapies pipeline is robust with more than 29 pharmaceutical companies developing over 35 therapies targeting autoimmune diseases, graft-versus-host disease, and transplant rejection. Key players like Orca Bio, Cellenkos, and Quell Therapeutics are progressing candidates through various clinical stages, including late-stage trials. These therapies leverage regulatory T cells to restore immune balance, potentially offering more precise and safer treatment options. Continued clinical progress and regulatory reviews, such as Orca-T's FDA evaluation, highlight a promising future for these innovative immunotherapies.
JM Smucker reported fiscal Q4 2026 adjusted earnings of $2.77 per share, surpassing analysts' $2.64 estimate, with net sales up 6% to $2.268 billion. Growth was driven by a 12% increase in U.S. retail coffee sales, aided by pricing actions and strong...
Technology stocks saw a sharp decline after an initial morning rally faded, with the semiconductor-focused ETF SOXL plunging 16.43% and AMD dropping nearly 7%. The selloff was driven by active short selling and investor caution ahead of the upcoming ...
ERShares has implemented measures to protect long-term investors in its XOVR ETF, which holds private exposure to SpaceX, ahead of SpaceX's expected historic IPO on June 12. The fund will restrict large creation orders and may impose up to 2% redempt...
Velo3D has formed a strategic partnership with Aurelia Technologies to enhance additive manufacturing for next-generation gas turbines. This collaboration aims to improve design efficiency and supply chain resilience, potentially lowering production ...
As of May 31, 2026, EssilorLuxottica disclosed its total number of shares at 463,289,594 and actual voting rights at 459,253,760, excluding treasury shares. The company enforces a 31% voting rights cap per shareholder according to its bylaws. This tr...
